Interleukin 1beta, IL1beta, Catabolin, IL-1 beta, IL1B, Interleukin 1 Beta, IL1F2, Pro-Interleukin-1-Beta, Preinterleukin 1 Beta, Interleukin-1 Beta, IL1-BETA, IL-1, Interleukin-1beta, IL-1B

KO Status

F2 (-/-)

Drug Information

Launched drugs: 4
Drugs in clinical trials: 7
Latest Research Phase: Approved

Drug Name





Clinical Trials




Novartis Pharma Ag

Diabetes Mellitus, Type 1, Familial Mediterranean Fever, Prediabetic State, Cytokine Release Syndrome, Still's Disease, Adult-Onset, Atherosclerosis, Mevalonate Kinase Deficiency, Diabetes Mellitus, Type 2, Triple Negative Breast Neoplasms, Hereditary Autoinflammatory Diseases, Coronavirus Disease 2019 (COVID-19), Myelodysplastic Syndromes, Muckle-Wells Syndrome (MWS), Arthritis, Rheumatoid, Dry Eye Syndromes, Arthritis, Juvenile, Mucocutaneous Lymph Node Syndrome, Hyperimmunoglobulin D syndrome, Tumor necrosis factor receptor associated periodic syndrome, Cryopyrin-Associated Periodic Syndromes, Arthritis, Gouty, Colorectal Neoplasms, Osteoarthritis, Knee, Cognitive Dysfunction, Alzheimer Disease, Sarcoidosis, Pulmonary, Gout, Pulmonary Disease, Chronic Obstructive, Aortic Aneurysm, Abdominal, Melanoma, Peripheral Arterial Disease, Anemia, Sickle Cell, Diabetes Mellitus, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Behcet Syndrome, Macular Degeneration


K-17, NSC-66847, NSC-527179


Celgene Corp

HIV Infections, Myelodysplastic Syndromes, Spondylitis, Ankylosing, Multiple Myeloma, Erythema Nodosum, HIV Wasting Syndrome, Leprosy, Lepromatous, Carcinoma, Hepatocellular


KPL-914, RGN-303


Regeneron Pharmaceuticals Inc

Anemia, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn, Arthritis, Juvenile, Hyperlipoproteinemia Type I, Pericarditis, Cryopyrin-Associated Periodic Syndromes, Gout, Renal Insufficiency, Chronic


AC-201, AC-203, Art-50, SF-277, CCP-020, KW-4800, AC-201CR


Diabetes Mellitus, Type 2, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Epidermolysis Bullosa, Junctional, Osteoarthritis, Knee, Diabetes Complications, Pemphigoid, Bullous, Arthritis, Osteoarthritis, Osteoarthritis, Hip, Diabetes Mellitus, Epidermolysis Bullosa Dystrophica





Osteoarthritis, Knee, Osteoarthritis

HMPL-004 (Hutchison Medipharma)


Phase 3 Clinical

Hutchison Medipharma Ltd

Lupus Erythematosus, Systemic, Colitis, Ulcerative, Crohn Disease


HAS-CD24, CD24-Fc-IgG, MK-7110, MK7110, CD24-Fc

Phase 3 Clinical


Leukemia, HIV Infections, Hematopoietic stem cell transplantation (HSCT), Graft vs Host Disease, Coronavirus Disease 2019 (COVID-19), Myelodysplastic Syndromes, Dyslipidemias, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Melanoma


AB-7, S-78989, VPM-087, XOMA-052, XMA-005.2

Phase 3 Clinical


Acne Vulgaris, Diabetes Mellitus, Type 1, Pyoderma Gangrenosum, Diabetes Mellitus, Type 2, Carcinoma, Renal Cell, Esophageal Neoplasms, Stomach Neoplasms, Arthritis, Rheumatoid, Colorectal Neoplasms, Uveitis, Osteoarthritis, Behcet Syndrome, Labyrinth Diseases, Panuveitis



Phase 3 Clinical


Schnitzler Syndrome, ST Elevation Myocardial Infarction, Coronavirus Disease 2019 (COVID-19), Gout

Ajulemic acid

CT-3, HU-239, IP-751, DMH-11C, JBT-101, CPL-7075, DMH-THC-11-OIC

Phase 3 Clinical

Corbus Pharma

Cystic Fibrosis, Dermatomyositis, Scleroderma, Systemic, Lupus Erythematosus, Systemic, Scleroderma, Diffuse





Generation and annotation of the DNA sequences of human chromosomes 2 and 4

Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., Du H., Wilson R.K.,

Nature 434:724-731(2005)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase

Mizutani H., Schechter N., Lazarus G., Black R.A., Kupper T.S.,

J. Exp. Med. 174:821-825(1991)

Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1

Van Damme J., De Ley M., Opdenakker G., Billiau A., De Somer P., Van Beeumen J.,

Nature 314:266-268(1985)

Effects of hematopoietin-1 and interleukin 1 activities on early hematopoietic cells of the bone marrow

Zsebo K.M., Wypych J., Yuschenkoff V.N., Lu H., Hunt P., Dukes P.P., Langley K.E.,

Blood 71:962-968(1988)

The role of arginine residues in interleukin 1 receptor binding

Nanduri V.B., Hulmes J.D., Pan Y.C., Kilian P.L., Stern A.S.,

Biochim. Biophys. Acta 1118:25-35(1991)

IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells

Tominaga K., Yoshimoto T., Torigoe K., Kurimoto M., Matsui K., Hada T., Okamura H., Nakanishi K.,

Int. Immunol. 12:151-160(2000)

Rapid secretion of interleukin-1beta by microvesicle shedding

MacKenzie A., Wilson H.L., Kiss-Toth E., Dower S.K., North R.A., Surprenant A.,

Immunity 15:825-835(2001)

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis

Nakahara H., Song J., Sugimoto M., Hagihara K., Kishimoto T., Yoshizaki K., Nishimoto N.,

Arthritis Rheum. 48:1521-1529(2003)

cDNA cloning of IL-1 alpha and IL-1 beta from mRNA of U937 cell line

Nishida T., Nishino N., Takano M., Kawai K., Bando K., Masui Y., Nakai S., Hirai Y.,

Biochem. Biophys. Res. Commun. 143:345-352(1987)